ASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025

Stock News

Oct 27

ASCLETIS-B (01672) announced that its board of directors will present multiple obesity drug candidates, including ASC30 as well as the combination therapy of ASC31 and ASC47, in poster sessions at ObesityWeek® 2025 in Atlanta, Georgia, USA.

"We are excited to showcase the continued progress of our robust small-molecule and peptide obesity pipeline at ObesityWeek®," said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS. "These advancements fully demonstrate our strong commitment to developing highly differentiated obesity treatment solutions."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1183165298"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183165298\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183165298?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183165298","market":"sh","top_or_hot":-1,"title":"ASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025","media":"Stock News","content":"<p>ASCLETIS-B (01672) announced that its board of directors will present multiple obesity drug candidates, including ASC30 as well as the combination therapy of ASC31 and ASC47, in poster sessions at ObesityWeek® 2025 in Atlanta, Georgia, USA.</p>\n<p>\"We are excited to showcase the continued progress of our robust small-molecule and peptide obesity pipeline at ObesityWeek®,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS. \"These advancements fully demonstrate our strong commitment to developing highly differentiated obesity treatment solutions.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-27 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) announced that its board of directors will present multiple obesity drug candidates, including ASC30 as well as the combination therapy of ASC31 and ASC47, in poster sessions at ObesityWeek® 2025 in Atlanta, Georgia, USA.</p>\n<p>\"We are excited to showcase the continued progress of our robust small-molecule and peptide obesity pipeline at ObesityWeek®,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS. \"These advancements fully demonstrate our strong commitment to developing highly differentiated obesity treatment solutions.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"","article_id":"1183165298","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183165298","pubTimestamp":1761558855,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) announced that its board of directors will present multiple obesity drug candidates, including ASC30 as well as the combination therapy of ASC31 and ASC47, in poster sessions at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","01672":"歌礼制药-B"},"translate_title":"歌礼-B(01672)：歌礼将在ObesityWeek上展示ASC30口服片、ASC30注射液以及ASC31联合ASC47的研究结果®2025","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1},"content_text":"ASCLETIS-B (01672) announced that its board of directors will present multiple obesity drug candidates, including ASC30 as well as the combination therapy of ASC31 and ASC47, in poster sessions at ObesityWeek® 2025 in Atlanta, Georgia, USA.\n\"We are excited to showcase the continued progress of our robust small-molecule and peptide obesity pipeline at ObesityWeek®,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS. \"These advancements fully demonstrate our strong commitment to developing highly differentiated obesity treatment solutions.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}